introduced a resolution honoring May 17 as Diffuse Intrinsic Pontine Glioma (DIPG) Awareness Day to support expanded research for treatments and care for DIPG
Support expanded research for treatments and care for DIPG pediatric cancer.
Occurrences
U.S. Representatives Debbie Dingell (D-MI-06), David Joyce (R-OH-14), and Michael McCaul (R-TX-10), introduced a resolution honoring May 17 as Diffuse Intrinsic Pontine Glioma (DIPG) Awareness Day to support expanded research for treatments and care for DIPG, a deadly form of pediatric cancer.
It also included two bills that I lead – the Give Kids a Chance Act to expand research into childhood cancer and the Dr. Lorna Breen Health Care Provider Protection Act to prevent suicide and reduce burnout among health care professionals.
We must work together to continue the fight against childhood cancer by driving awareness, supporting research endeavours, and pursuing the treatments these children deserve.
Evidence
legacy_unverified · Source version not recorded · locator unknown
Mrs. Dingell submitted H. Res. 1295. The resolution says the House supports expanded research to better understand DIPG, develop effective treatments, and provide comprehensive care for children with DIPG and their families.
legacy_unverified · Source version not recorded · locator unknown
Public Law 119-75 includes Subtitle A, the Mikaela Naylon Give Kids a Chance Act. It expands FDA authority for molecularly targeted pediatric cancer investigations and amends the Program for Pediatric Studies of Drugs to authorize $25,000,000 for each of fiscal years 2026 through 2028.
Assessments
Dingell fulfilled the promise in federal office by sponsoring H. Res. 1295 in 2026, which directly supported expanded DIPG research, development of effective treatments, and comprehensive care for affected children and families. The resolution itself had not passed, but the promise was framed as support, and her sponsorship is direct candidate action in the same term. The broader 2026 pediatric cancer provisions also advance the research and treatment-development goal, though they are not DIPG-specific and the evidence does not show Dingell as a principal driver of that law.